|
|
Preparation for skin care, possessing antifungal properties (versions) Invention represents preparation for skin care, possessing antifungal properties and contains hydrochloride of 2-benzimidazolylcarbamic acid methyl ether, salicylic acid, dimethylsulphoxide and ethanol, with components in preparation being in specified ratio in wt %. |
|
Liquid balsam having local irritant and anti-inflammatory action Invention relates to a liquid balsam having antiseptic and local irritant action. Said balsam contains 5-36 wt % menthol-free peppermint oil, 8-43 wt % eucalyptus oil, 0.5-20 wt % pine oil, 13-57 wt % levomenthol, 1-25 wt % lavender oil, 1.5-36 wt % turpentine oil. |
|
Biofilm destruction compositions Invention refers to chemical-pharmaceutical industry, namely to biofilm destruction compositions containing from 0.005% to 10% of a biofilm destruction agent containing at least one compound specified in 1-decen-3-ol, cis-4-decen-1-ol, trans-2-decen-1-ol, cis-2-nonen-1-ol, cis-4-decenal, trans-2-decenal, cis-7-decenal, cis-5-octen-1-ol, trans-2-octen-1-ol, 1-octen-3-ol, cis-3-nonen-1-ol, trans-2-nonen-1-ol, cis-6-nonen-1-ol, 9-decen-1-ol, trans-2-undecen-1-ol, trans-2-dodecen-1-ol, trans-2-octenal, trans-2-nonenal, cis-6-nonenal, trans-2-undecenal, trans-2-dodecenal, their stereoisomers and mixtures, a therapeutically active substance; and a carrier. |
|
Pharmaceutical composition, including dissolving mixture and vitamin d derivative or analogue Claimed is stable in storage water-free composition for local treatment of psoriasis by application on skin, including homogeneous mixture of therapeutically effective quantity of calcipotriol in dissolved form; dissolving mixture, consisting of solvent based on fatty acid triglycerides, auxiliary solvent, selected from polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether, polyoxypropylene-3-myristyl ether, polyoxypropylene-5-ceteth 20; and lipophilic penetration enhancer, selected from N-alkylpiperidone, N-alkylpyrrolidone, such as N-methylpyrrolodone, N-hydroxyalkylpyrrolidone or 2-pyrrolidone; where ratio of solvent, auxiliary solvent and penetration enhancer is in range from 50:25:25 to 75:10:15; and where said dissolving mixture is included into composition in amount, sufficient for effective calcipotriol dissolution, and water-free pharmaceutically acceptable carrier, including at least one paraffin. |
|
Group of inventions relates to medicine, namely to oncology, and deals with application of SNS-595 for treatment of subject with cancer, with reduced BRCA2 activity. For this purpose SNS-595 is introduced in therapeutically effective quantity. |
|
Method of treating demodectic mange in cattle Invention refers to veterinary science and aims at controlling demodectic mange in cattle. As an insectoacaricide, a composition is used in the following mixture ratio, wt %: abamectin - 0.1; fipronil - 0.5; dimehyl sulphoxide - 10; ethyl cellulose - 30-40; polyethylene glycol - 1,500 - 16; isopropyl alcohol - the rest up to 100. The composition is used by local applications on the affected areas of the animal's skin. |
|
Method for protection of cattle from ixodic ticks Insecticidal-acaricidal agent is used as a composition with the following ratio of components, wt %: abamectin - 0.1; fipronyl - 0.5; dimethyl sulfoxide - 10; ethyl-cellulose - 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest to 100. The composition is used by the method of application to the region of dewlap, shoulder, hip and abdomen in a dose of 20 ml per animal. |
|
Antiseptic compositions and applications thereof Group of inventions refers to antiseptic compositions and applicable for disinfection of surfaces, such as body surfaces, and for treatment of infection-related conditions. As active ingredients, an antiseptic composition contains menthol and silver ions, and a pharmaceutically acceptable carrier. The silver ion concentration in the composition makes from 0.25 mM to 0.6 mM, whereas the menthol concentration makes from 0.64 mM to 6.4 mM. What is also presented is an antiseptic kit containing the above composition and a packaging material. Other embodiments involve a method for producing the above antiseptic composition, a method for reducing the silver ion concentration in the antiseptic composition and a method for increasing the antiseptic activity of the above composition. |
|
Antibacterial pharmaceutical composition of clotrimazole and method for making it Invention represents an antibacterial pharmaceutical composition containing clotrimazole, propylene glycol, macrogol 400, macrogol 1,500, macrogol 4,000, poloxamer 338, cetostearyl alcohol, macrogol 20 cetostearyl alcohol, disodium edetate, purified water with the ingredients of the compositions taken in certain proportions, g/100 g. |
|
Method of treating bronchial asthma Treating bronchial asthma is ensured by superior laryngeal nerve anaesthesia with 0.5% Novocaine mixed with 96° rectified ethyl alcohol for the purpose of bronchial spasmolysis in bronchial asthma. |
|
|
Invention refers to a melanin production inhibitor and a topical preparation, such as a cosmetic preparation. The invention represents a melanin production inhibitor containing a compound presented by the following general formula (1) (except clotrimazole), and/or its pharmacologically acceptable salt, as well as a topical preparation applicable for melanin production inhibition and containing the melanin production inhibitor. |
|
Method of treating perforations and disruption of lower one-third of oesophagus Invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained. |
|
|
Method of treating degenerative-dystrophic diseases of locomotor apparatus Composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days. |
|
|
Skin care agent possessing antifungal properties Invention refers to pharmaceutical industry and represents a skin care agent possessing the antifungal properties, containing propolis, ethanol, and a sulphur-containing component, differing the fact that the sulphur-containing component contains elemental nanodispersed sulphur with the components of the agent taken in certain amounts, wt %. |
|
|
Method of therapy of endometritis of cats and dogs Method comprises administering an agent containing gentamicin, gamavit, sodium benzoate, potassium sorbate and propylene glycol. The agent is used in intrauterine mode 2 times a day for 7-10 days at a dose of 5-10 ml to cat and 10-20 ml to dog. |
|
|
Agent for treatment of inflammation of udder of cows Agent for treatment of inflammation of udder of cows comprises 10-12 g of crystalline iodine, 100-102 g of polyvinylpyrrolidone and additionally in 1000 g/ml: emulsion wax 10-12; glycerol monostearate 50-52; beewax 10-12; refined sunflower oil 77-78; medical vaseline oil 28-29; glycerol 35-37; purified water - the rest to 1000 ml. |
|
|
Method for minimally invasive treatment of internal haemorrhoid Method refers to medicine, namely to surgery. Terminal branches of the superior rectal artery are underrun and ligatured 2.5-3.0 cm above a dentate line. That is combined with fixing the internal haemorrhoids with the same figure-of-eight sutures. A sclerosing preparation is administered into the submucous membrane of the haemorrhoids below the sutures. |
|
|
Invention represents a coronarodilating medication in the form of a tablet, which contains a solution of levomenthol in menthyl isovalerate (validol), isomalt, and calcium or magnesium stearate. |
|
|
Composition for oral application, containing cooling substance Invention relates to a composition for treating throat pain in the form of dispersible tablets. The claimed composition contains an endothermic cooling substance, representing xylitol, in an amount of 1-10 wt/wt % and an active substance, which contains menthol and 2,4-dichlorobenzyl alcohol and amylmetacresole. |
|
|
Invention relates to versions of a compound of formula where R1 is a hydrogen atom; R2 is a lower alkyl group; P is H; , where P1, P2 and P3 are identical or different and are selected from a hydrogen atom, a lower alkyl group and a C14-C22 alkenyl group substituted with a lower alkyl group; or where P1 is an alkenyl group, and each of P2 and P3 is a hydrogen atom; and Y is a C14-C22 alkenyl group with at least one double bond having a Z-configuration, and having a first double bond at the third carbon-carbon bond from the omega (ω)-end of the carbon chain, capable of lowering the level of triglycerides and cholesterol, a pharmaceutical or lipid composition based on the disclosed compounds, as well as use (versions) of the disclosed compounds. |
|
Method of treating skin diseases in sheep Invention refers to medicine, namely veterinary science, and may be used for treating skin diseases in sheep. That is ensured by preparing the affected skin. The affected skin is prepared with 70% ethanol. That is followed by processing the affected skin with electrochemically activated water using a spray head first with an acid fraction at pH 3.0 in the amount of 20-30 ml per the surface of 10 cm2 for 10-15 seconds at 15-20 cm. That is followed by keeping for 25-30 minutes and processing with an alkali fraction at pH 11.00 in the amount of 20-30 ml per the surface of 10 cm2 for 10-15 seconds at 15-20 cm. The skin is processed twice a day. |
|
|
Pharmaceutical composition containing vitamin d analogue and mixed co-solvent and surfactant Invention refers to pharmaceutical industry, and represents a local skin composition which is an oil-in-water-in-oil emulsion containing a water phase with a dispersed lipophilic phase containing calcipotriol or monohydrate in the dissolved form; a non-ionic surfactant specified in a group consisting of polyethylene glycol glycerides and C6-20 fatty acids, polyoxyethylene C8-20 alkyl ethers or polysorbates and a lower alkanol as a co-solvent; the above water phase is dispersed in a pharmaceutically acceptable anhydrous lipophilic carrier or base. |
|
Invention refers to medicine, namely to anaesthesiology, and may be used as an anaesthesia care of a surgical intervention for carotid endaterectomy or internal carotid artery resection after pathological deformation thereof. That is ensured by general anaesthesia in a combination with deep and superficial cervical plexus blockade. Pre-medication is used the day before the operation and on the operative day in the morning. Diazepam is introduced intramuscularly 30 minutes before the operation in a combination with phentanyl; the introduction is followed by ECG monitoring and heart rate count, plethysmography with arterial blood saturation, non-invasive blood pressure measurement and neuromonitring according to a bispectral index or entropy. Catheterisation of patient's peripheral or central vein is followed by an infusion therapy, an ionotropic therapy, a cardiotropic therapy, peripheral resistance maintenance. If heart rate is no more than 80 beats per minute, the anaesthesia is induced to reach an anaesthetic depth according to the bispectral index or entropy within 40-60 units. Analgesia is provided by the intravenous introduction of 0.005% phentanyl; myoplegia is ensured by the intravenous introduction of a myorelaxant. After tracheal intubation, the patient is transferred to forced volumentic artificial pulmonary ventilation with the CO2 level within 35-45 mm Hg according to capnography. The anaesthesia is maintained by supplying an inhalation anaesthetic to the steam level of 0.8-1.0 MAK 0.8-0.9 litre of the air and oxygen flow containing 50% oxygen with controlling the inhalation anaesthetic volume by the level of the anaesthetic depth according to the bispectral index or entropy. That is followed by deep cervical plexus blockade. A tubercle of the VI cervical vertebra (a carotid tubercle) and a mastoid process are localised; thereafter a line connecting the above reference points is drawn on skin. The second line is drawn 1 cm below the first one in parallel. To verify an injection point of a local anaesthetic, the spines of IV, III, II cervical vertebras being at 1.5 cm from each other are palpated, and the reference point is the VI cervical vertebra. The needle is inserted perpendicularly to the skin and slightly in the caudal direction to reach the spines. The anaesthetic is introduced in a dose of 5-7 ml in each point C4, C3, C2. Another 5-7 ml of the anaesthetic is introduced in a point found in an apex of the mastoid process. The superficial cervical plexus blockade requires introducing he fan-shaped introduction of the anaesthetic solution in a dose of 15 ml in a point found in the middle of a lateral crus of the nodding muscle under the above muscle, 4-5 ml in each direction from the same point; the first and following injections are performed at a depth of a usual intramuscular needle perpendicularly to nodding muscle. |
|
|
Improvement of compositions or whatever is relevant to compositions Invention relates to pharmaceutical industry and represents suitable for ingestion composition in form of particles for pain relief and reduction of inflammation in throat, which contains: a) at least one compound, selected from group, which consists of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol and benzydamine; and b) bio-adhesive material in quantity to 10 wt %, and c) bicarbonate and/or organic acid, with particles having size less than 1 mm. |
|
Menthol derivative compounds and using them as active systemic agents and oral agents Invention refers to medicine, particularly to pharmacy and dentistry, and concerns creating new compositions of menthol derivatives. For this purpose, 2-isopropyl-5-methylcyclohexyl-2-hydroxyphenylcarbamate is suggested to be used as an antioxidant, anti-inflammatory and antimicrobial agent for local treatment of the oral cavity, e.g. periodontal diseases. That provides the basis to present the compositions containing an effective amount of 2-isopropyl-5-methylcyclohexyl-2-hydroxyphenylcarbamate, and at least one excipient. |
|
Invention refers to a new lipid compound of general formula , wherein n=0; R1 and R2 are identical or different, and may be specified in a group of substitutes consisting of a hydrogen atom, a C1-C7alkyl group, a halogen atom and a C1-C7alkoxy group; X represents COR3 or CH2OR4, wherein R3 is specified in a group consisting of hydrogen, hydroxy, C1-C7alkoxy and amino; and R4 is specified in a group consisting of hydrogen, C1-C7alkyl or C1-C7acyl, Y represents C9-C21 alkene with one or more double bonds in E- or Z-configurations with the chain Y being unsubstituted and containing a double bond in the ω-3 position; provided R1 and R2 cannot simultaneously represent a hydrogen atom. |
|
Composite veterinary preparation and method for preparing it Group of inventions refers to veterinary science and biotechnology and aims at immune correction and detoxification. A method involves hydromechanical preparation of a porous carbon material and drying of the product. Betulin is dissolved in ethanol at mass ratio of betulin: ethanol 0.01-0.06:1 or in an ethanol-glycerol solution at mass ratio of betulin: glycerol: ethanol 0.03:0.14:1. Then it is dispersed in a porous structure of a carbon carrier by betulin impregnation in ethanol or ethanol-glycerol solution in mass ratio of betulin: carbon carrier 0.4-1 at room temperature and mixing. That is followed by ethanol and drying. The ready preparation contains, wt %: betulin 0.5-1.8, glycerol 0-5, carbon carrier - the rest, and is characterised by granula size 0.5-0.8 mm and specific absorption surface 170-250 m2/g. |
|
Invention relates to medicine, namely to medication for promotion of survival of obtained from bone marrow mesenchymal stem cells in vivo and differentiation in cadiomyocytes. Application of traditional Chinese medical composition for obtaining medication for promotion of survival of obtained from bone marrow mesenchymal stem cells in vivo and differentiation in cadiomyocytes. Traditional Chinese medication composition (versions). Method of treatment and prevention of cardiovascular disease, including introduction to patients who need it of efficient quantity of traditional Chinese medical composition, and mesenchymal stem cells, obtained from bone marrow. |
|
Pharmaceutical composition for treating burns Invention refers to a pharmaceutical composition for treating burns containing oxidised dextran of molecular weight 35-65 kDa as an active ingredient; as excipients for symptomatic therapy of burns it contains anaesthesine, polyethylene oxide of molecular weight 1.5-6.0 kDa, metronidazole, phosphatidylcholine and a pharmaceutically acceptable carrier in the following proportions, wt %: oxidized dextran - 0.5-5.0; anaesthesine - 0.5-2.5; polyethylene oxide - 0.5-5.0; metronidazole - 0.1-0.2; phosphatidylcholine - 1.0-2.0; pharmaceutically acceptable carrier - the rest. As a pharmaceutically acceptable carrier, the composition may contain purified water or physiologic saline or 10 mM phosphate buffer with pH 7.4. |
|
Method of automatic assessment of skin and/or wrinkle texture Group of inventions relates to cosmetology. Method includes stages at which processing of skin image is performed, which includes cross conversion to binary form and/or processing by comparison of short linear segments to obtain 10 or more types of physical parameters, related to dermal furrow; then physical parameters, obtained at previous stage are substituted into prediction formula. Prediction formula is determined by multi-variant analysis of 10 or more types of physical parameters, related to dermal furrow, and visual assessment values, distributes by categories from third to tenth degree, related to skin and/or wrinkle, obtained from a number of samples in order to obtain assessment value by categories from 3 to 10 degree and assessment of obtained assessment value as assessment result with respect to skin and/or wrinkle texture. Described are device for assessment of skin texture and method of selecting medication for external application on skin, which uses assessment method or device. |
|
Invention relates to medicine, namely to anesthesiology, and can be used in patients during and after highly traumatic operations on thoracic and lumbar spine. For this purpose general anesthesia is performed with sevoflurane. Additionally during operation epidural analgesia is performed by infusion of mixture of 0.2% solution of ropivacaine with fentanyl 2 mcg/ml and adrenalin 2 mcg/ml at rate 5-10 ml/hour. In postoperative period anesthesia is performed by constant infusion of mixture at rate 4-8 ml/hour. |
|
|
Method of sclerosing therapy of hemorrhoid with use of vibroacoustic exposure Invention refers to medicine, namely surgery, and may be used for sclerosing therapy of hemorrhoid. That is ensured by the sclerosing therapy by introducing a detergent into a hemorrhoid. It is immediately followed by a vibroacoustic session above the sclerosed hemorrhoids. The vibroacoustic session is performed in the frequency range of 0.26 kHz and 0.55 kHz alternatively 30 sec each for 3 minutes. |
|
|
Method of treating acute and chronic deep caries of teeth with complex medication Invention relates to dentistry and deals with treatment of acute or chronic deep caries of teeth. After preparation of caries cavity and its treatment with 3% solution of hydrogen peroxide, medicinal liner with complex medication of definite composition is applied on the bottom of caries cavity. In preparation of medication the following components of composition are used: ecdysterone - 0.05 g; apilac - 0.5 g; essential clove oil - 0.5 g; ethyl alcohol 30% - 5 ml; as the base used are olive oil and bee wax in mass ratio (7:3) - 94.5 g. After that isolating liner and temporary or permanent filling are applied. |
|
|
Preparation for treatment and prevention of postpartum endometritis in cows Invention relates to field of veterinary. Preparation for treatment and prevention of postpartum endometritis in cows has the following composition, wt %: norfloxacin hydrochloride - 1.0-3.5, dioxidine -1.0-3.5, dimethyl sulfoxide -10.0, glycerol - 10.0; 1,2 propylene glycol - 10.0; sunflower refined oil - 12.5, emulsion wax - 1.0, stearic acid - 1.0, water for injections - to 100%. |
|
Method of treating cervical cancer Invention refers to medicine, namely oncology, and can be used for treating cervical cancer. That is ensured by radiation teletherapy and brachytherapy. Each brachytherapy session is preceded by bringing the Hydrogel Coletex-M Tissue 3-5 ml to the tumour before 12-18 hours. Before gel contact, the Coletex-M Tissue is introduced. Further,1-1,5 hours prior to the brachytherapy session, the textile tissue is removed, and Hydrogel Coletex-ADL Tissue 4-6 ml is brought to the tumour. Preliminary, the Hydrogel Coletex-ADL Tissue is added with lidocaine to achieve the gel concentration 4-6%. |
|
|
Invention refers to pharmacology, and represents a sterile injectable water-based composition in the form of gel for iintra-articular injection containing hyaluronic acid of molecular weight 0.1 to 10×106 Da in the amount of 1-100 mg/ml of water or one of its salts and optionally one or more other natural polysaccharides specified in a group consisting of chondroitin sulphate, keratan, keratan sulphate, heparin, heparan sulphate, cellulose and its derivatives, chitosan, xanthan, alginate and their salts, and also one or more polyalcohols in the amount of 0.0001-100 mg/ml of water, prepared by making a water-based formulation containing hyaluronic acid or one of its salts, optionally one or more other natural polysaccharides, and also one or more polyalcohols, sterilising it with wet steam; the prepared gel shows a coincidence frequency of the elasticity modulus G' and the viscosity modulus G" within the range 0 to 10 Hz preferentially 0.41 Hz ±0.41 Hz with G" exceeding G' if the coincidence frequency is found to be high. |
|
Method of ethanol sclerotherapy of cystic transformed thyroid nodules Invention refers to medicine, namely endocrinology, and concerns ethanol sclerotherapy of cystic transformed thyroid nodules. That is ensured by ultrasound-aided puncture of a cystic cavity and complete aspiration of its content. Then 95% ethanol is introduced in the cavity and exposed for 1-2 minutes. Then, mixed ethanol and rest cystic content are reaspirated with the procedure conducted more than once to produce pure transparent liquid after aspiration. |
|
|
Complex for treating poisonings containing phenothiazine compound and method of treating poisonings Invention refers to medicine and describes a pharmaceutical complex for correcting metabolic disorders in patients suffered from toxic poisonings, containing a phenothiazine compound being methylene blue, a nitrate ester compound being nitroglycerin, ethanol and a pharmaceutically acceptable carrier. Also, there are described methods of treating flouroacetate, ethylene glycol and cyanide poisoning involving introducing an effective amount of the declared complex into a patient in need thereof. |
|
Use of alpha-hydroxycarbonyl compounds as reducing substances Declared invention refers to chemical-pharmaceutical industry and concerns the use of alpha-hydroxycarbonyl compounds as reducing substances able to form cyclic dimers. Also, there are presented related methods for reducing the reduced compounds, especially activated by compound reduction. The examples of the used alpha-hydroxycarbonyl compounds are dihydroacetone, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone. |
|
Method of combined xenon anaesthesia in oncological patients Invention refers to medicine, namely, to anesthesiology and oncology, and can be used as an anaesthesia care of surgical interventions in oncological patients. For this purpose, after the entry to operating theatre, an epidural cavity is punctured at the level T4-T11 followed by introducing lidocaine 40 mg. Thereafter, the epidural cavity is catheterised with a catheter which is inserted to infuse an analgesic mixture consisting of 0.2% ropivacaine 47 ml, 0.005% phentanyl 2 ml and 0.1% adrenaline 0.1 ml at 15 ml/hour for 20 min, and then the rate of administering is reduced to 7-10 ml/hour. In 20-25 min after the beginning of the epidural administration of the mixture, 0.005% phentanyl 2 ml and 0.1% atropine 0.5-0.6 ml are introduced intravenously. It is followed by propofol induction in dose 2-2.5 mg/kg with accompanying intubation of the patient. 100% Oxygen semiopen circuit denitrogenisation is performed. The denitrogenisation procedure is attended by the intravenous propofol anaesthesia in dose 4 mg/kg/hour. After the closed circuit is enabled, a breathing bag is left filled with no more than 500 ml, and the flow is dropped to zero. A phase of fast saturation Xe 1.3-1.5 of patient's pulmonary capacity under control of FiO2 follows to reduce the oxygen concentration in the breathing circuit equal to 40%. If achieving Xe 60%, the flow is set at 250-400 ml a minute to provide a stable balance. After the stable balance is provided in the relation Xe:O2 60:40, the Xe flow is reduced to 0-160 ml/min, while oxygen is supplied to the circuit in dose 4 ml/kg. At the traumatic operative stages, boluses of phentanyl 0.1 mg is gradually introduced. |
|
|
Method for intensive care of multiple-organ-failure syndrome Invention refers to medicine, particularly anesthesiology and intensive care, and can be used for treating multiple-organ-failure syndrome in the patients who underwent cardiac surgeries. That is ensured by evaluation of the risk factors of developing multiple-organ-failure syndrome. Their absence enables standard intensive care. If within 12 hours after the cardiac surgery there are observed acute reduced cardiac output and reduced ejection fraction with the combined introduction of adrenaline and dobutamine appeared to be ineffective, differentiated interventional therapy of multiple-organ-failure syndrome is performed with using a calcium-sensitising agent taken among the cardiac support. The presence of haemodynamic criteria of acute lung injury combined with systemic inflammation response, prolonged renal replacement therapy in continuous veno-venous hemofiltration is performed. It is combined with a simultaneous complex of respiratory kinesiological rehabilitation with differentiated selection of a respiratory support method. On the forth day of artificial pulmonary ventilation, puncture-dilatation tracheostomy is performed. |
|
|
Method of treating coronary insufficiency in simulated myocardial ischemia Invention refers to experimental medicine and can be used for developing molecular methods of treating coronary insufficiency. For this purpose, the simulated myocardial ischemia requires experimental myocardial injections of an endotheliocyte growth factor gene in the form of the phVEGF165 vector at 50-100 mcg/cm2 of an ischemic region at an area pitch of 5 mm. 2-dimethylaminoethanol is added to the vector preparation to provide more effective myocardiocyte transfection. |
|
FIELD: medicine. SUBSTANCE: invention is used for treatment venous malformations, administered by means of injections. The declared preparation contains ethanol with the degree of cleanliness from 70 to 99 % which is necessary for the effect causing sclerosis, a difficult ethyl ester of the iodated fat acid, and in addition contains ethyl cellulose or dextrin, providing viscosity of the solution from 10 to 700 cPz, for the preparation of gel with the emboli effect. EFFECT: declared drug provides reliable application at all stages of course of the treatment and ability to formation of a selective steady sclerosis, also the invention provides biological compatibility, high ability to densifying, formation of biodegrading derivatives, an exception of local or system toxic effects. 6 cl, 1 tbl, 2 ex |
|
FIELD: medicine. SUBSTANCE: group of inventions refers namely to dermatology and can be used for prevention and treatment of the pustulous diseases caused by bacterial skin defeats. For this purpose the damaged skin amazed and adjoining areas are worked with the antiseptic of "Likvacid" received with the use of trinol by means of its preliminary dissolution in a dimethyl sulfoxide in the ratio 1 mas.h. to 0,9 mas.h., accordingly, at the temperature not below indoor temperature before dark blue coloring of a mix occurs, and mixture then with a filler based on alcohol with addition of glycerin and further filtration of the received mix, herewith using as a filler of a solution of acid in ethyl spirit with its initial concentration accepted that the end-product has not less than 70 %, and with a choice of all components in the following ratio, mas.: trinitrotoluene- 0,25-1,5, a dimethyl sulfoxide - 1,0-10,0, acid - 0,5-1,0, glycerin - 17,5-23,0, ethyl spirit - the rest. The skin is greased with a wadded tampon with frequency of 2-3 times a day. Thus duration of therapy is not less than 17 days and to epulosisof the damaged surface. Or in case of the second invention grease the damaged skin and adjoining areas are greased with a wadded tampon with frequency of 2-3 times a day. The therapy course is not less and in addition is accepted than 10 days by taking "Likvacid" per oral 2-3 times a day within no more than 10 days. Herewith adults people take 11-16 ml, young men to 18-year-old age - 5-10 ml. EFFECT: the use of the given inventions allows carrying out effective preventive maintenance and treatment in case of optimum terms of therapy. 2 tbl, 1 dwg |
|
Hydrogel composition for treating burns Invention refers to medicine, particularly to dermatology, and represents a hydrogel composition for treating burns, containing immobilised active and auxiliary ingredients and a gelling ingredients, differing by the fact that as an active component it contains a drug substance of 2-allyloxyethanol in amount 0.1 to 10.0 (wt %), as auxiliary ingredients it contains a drug substance of lidocaine in amount 0.1 to 5.0 (wt %) or drug substances of lidocaine in amount 0.1 to 5.0 (wt %) or dezoxynate in amount 0.1 to 5.0 (wt %), as a gelling ingredient it contains hydroxypropyl cellulose in amount 0.1 to 5.0 (wt %). |
|
|
Method of treating cholelithiasis Invention relates to field of medicine and can be used for treatment of cholelithiasis, cholesterosis, sludge and calculous cholecystitis, developing at the background of cholesterol stones in bile bladder. Dehydration of cholesterol stones is carried out. 70% ethyl alcohol is introduced into bile bladder cavity in volume of bladder. Exposition is 1.5-2 minutes long. After that thranscutaneous transhepatic intrabladder fractional introduction of methyl-tert-butyl ether is performed. |
|
|
Method for reservatrol-based osteoporosis correction and fragility fracture prevention Reservatrol efficacy is studied in female Wistar rats with simulated osteoporosis by bilateral ovariectomy. For osteoporosis correction, reservatrol is administered in animal intraperitoneally for eight weeks after ovariectomy daily once a day in single dose 2 mg/kg. Osteoprotective action of reservatrol is estimated by a bone tissue microcirculation level and width of trabeculas of bone. |
|
|
Method for reservatrol and enalapril based osteoporosis correction and fragility fracture prevention Efficacy is studied in female Wistar rats. Osteoporosis is simulated by bilateral ovariectomy. Osteoporosis is corrected by intraperitoneal introduction of reservatrol 2 mg/kg and intragastric introduction of enalapril 0.5 mg/kg daily once a day for eight weeks after ovariectomy. Osteoprotective action of reservatrol combined with enalapril is estimated by a bone tissue microcirculation level and width of trabeculas of bone. |
|
|
Invention relates to a disinfectant used on hands and skin. The disinfectant contains (a), (b), (c), (d) and (e), but no other microbiocidal disinfecting agents meant for microbiocidal disinfection: (a) 40-90% ethanol, isopropyl alcohol or mixture thereof; (b) lactic acid in amount of 0.1-2% relative the entire weight of the disinfectant; (c) citric acid in amount of 0.01-2% relative the entire weight of the disinfectant; (d) zinc-containing compound which frees a zinc ion in a solution, in amount of 0.001-0.1% relative the entire weight of the disinfectant; (e) one or more pharmaceutically acceptable carriers for supplementing to 100% of the weight of the entire disinfectant. |
|
Method of transmembrane dialysis of purulent wounds Invention relates to medicine, namely, to surgery, and can be applied for treatment of purulent wounds of various etiology. For this purpose on surface of purulent wound applied is membrane capsule, filled with sorbent. As membrane capsule used is membrane bandage, which consists of polypropylene capsule, which hermetically fixed on it film. Cavity of polypropylene capsule is connected with membrane film, made from polyhydroxyalkanoate with pore size 2.7-3.0 nm, and is filled with dialysing solution, which consists of mixture of 100 ml Octenisept and 6 grams of enterosorbent Polysorb MP. Replacement of dialysing solution in membrane bandage is carried out in postoperative period daily during 10-12 days. |
Another patent 2551111.